Mainstream

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Post ContentdawnRead More

You might also be interested in reading The Bitcoin ‘Dream Entry’ To Wait For Before The Run-Up To $300,000.

August 6, 2025
In Mainstream